Neovii Pharmaceuticals AG services

Stem cell transplantation is a potentially curative procedure and an established therapeutic option for a number of diseases, primarily malignant diseases of the blood. In recent years, stem cell transplantation has also become an alternative therapeutic option for the treatment of other serious diseases, such as some autoimmune diseases.

Aplastic anemia is a rare, but serious hematological disease caused by a failure or deficiency of the bone marrow to produce blood cells (erythrocytes, leukocytes, and platelets). Patients with aplastic anemia are at risk of life-threatening infections or fatal bleeding. Curative treatments for aplastic anemia include immunosuppressive therapy, and/or hematopoietic stem cell transplantation.

Neovii actively seeks in-licensing and acquisitions opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs in particular in the areas of transplantation, hemato-oncology, and immune disorders.

Organ transplantation is a lifesaving procedure for end-stage organ failure. Solid-organ transplantation involves replacing the diseased or failing organ with a new, healthy one. Commonly transplanted organs are the kidney, liver, heart, and lung.

Autoimmune diseases are characterized by a dysregulation of the immune system. The result is an immunologic attack against the own body and/or body tissues leading to organ and tissue damage. A large number of different autoimmune diseases have been recognized.